ER-Low Positive Breast Cancer: Is Endocrine Therapy Needed?

When your pathology report shows ER-low positive breast cancer, it means that a small percentage (between 1% and 10%) of your cancer cells have receptors for estrogen ^[1]. Because there are some estrogen receptors, the cancer is not considered completely estrogen receptor-negative ^[1]. However, because the number of receptors is so low, the benefit of endocrine (hormone) therapy is less certain than it is for tumors with higher ER levels ^[1].

Receiving an ambiguous result like this can feel confusing or frightening, but this guide will help you prepare for discussions with your care team about treating early-stage disease. (Note: The term “upper-outer quadrant” simply describes the location of the tumor in the breast and does not change what ER-low means or how endocrine therapy is used).

What Does ER-Low Positive Mean?

Estrogen receptor (ER) expression is a spectrum. Pathologists test your tumor and report the percentage of cells that have these receptors ^[1]:

• ER-negative: Less than 1% of cells have receptors.
• ER-low positive: Exactly 1% to 10% of cells have receptors ^[1].
• ER-positive (>10%): More than 10% of cells have receptors. Generally, the higher the percentage, the clearer the expected benefit from endocrine therapy ^[1].

Biologically, ER-low positive breast cancers often look and behave more like ER-negative cancers ^[2]. They tend to grow faster and have a higher grade ^[2]. If a cancer is ER-negative, Progesterone Receptor (PR)-negative, and HER2-negative, it is called triple-negative breast cancer (TNBC). Because ER-low tumors still have some estrogen receptors, they are not technically triple-negative and shouldn’t automatically be treated exactly the same way ^[3]. Your full treatment plan will depend heavily on your HER2 status, PR status, tumor size, and whether cancer is found in your lymph nodes.

What else to look for on your pathology report:
To understand your complete diagnosis, look for your Progesterone Receptor (PR) percentage, HER2 status, tumor grade, tumor size, and lymph node status.

Why Pathology Results Can Differ

Because the difference between less than 1% (negative) and 1% to 10% (low positive) is very small, these borderline results can be challenging for laboratories to classify ^[4]. Tumors can be mixed (heterogeneous), and a difference between a small needle biopsy and the final surgical tumor does not always mean the first test was wrong; it may just represent sampling differences ^[4].

Medical guidelines recommend that laboratories have specific quality controls to double-check ER results between 0% and 10% ^[1]. If your ER-low result does not match other features of your tumor, your doctor may ask a breast pathologist to review the slides again or re-test the tissue ^[5][6].

Is Endocrine Therapy Recommended?

Endocrine therapy (hormone therapy) reduces estrogen levels or blocks estrogen from fueling cancer cells to lower the risk of the cancer returning. Because there are no large, randomized clinical trials specifically for ER-low cancers, the evidence for its use relies on reviews of past patient records (observational data) ^[7].

• Should I take it? Many doctors will still discuss and offer endocrine therapy because observational studies show an association with improved overall survival and a lower risk of recurrence ^[7].
• Residual disease: Some observational data suggest that patients who had some cancer remaining after receiving chemotherapy before surgery (residual disease) had a stronger association with survival benefits from endocrine therapy ^[3][8]. This is one factor your team will use to individualize your recommendation, but it does not mean endocrine therapy is mandatory or guaranteed to work.
• Medication options: Endocrine therapy is not uniformly a daily pill.
  • Tamoxifen (pill) blocks the estrogen receptors.
  • Aromatase inhibitors (pill) lower estrogen production. If you are premenopausal, an aromatase inhibitor must be combined with ovarian function suppression (typically monthly injections or surgery to stop the ovaries from making estrogen) ^[9].
  • For postmenopausal people, aromatase inhibitors or tamoxifen are commonly used ^[10][11].
• Duration: For early-stage breast cancer, the typical duration is about 5 years, though this can be shorter or longer depending on your individual recurrence risk, menopausal status, and how well you tolerate the medication ^[12][13].

Weighing Benefits and Side Effects

Because the expected benefit of endocrine therapy is generally smaller in ER-low cancer than in cancers with higher ER levels, it is crucial to weigh the potential advantages against the side effects ^[7][14]:

• Common effects: Hot flashes, joint and muscle aches, mood changes, and sexual symptoms such as vaginal dryness ^[15][16].
• Important risks: Aromatase inhibitors can cause bone loss, requiring regular bone density monitoring ^[11]. Tamoxifen carries rare but serious risks, including blood clots and endometrial (uterine) cancer ^[11]. Seek urgent medical attention if you experience leg swelling, shortness of breath, or abnormal vaginal bleeding.
• Fertility and Pregnancy: Endocrine therapies are not safe to take during pregnancy. If you plan to become pregnant, you must discuss fertility preservation and contraception with your care team before starting treatment.

Chemotherapy and Other Treatments

Because ER-low tumors frequently share aggressive traits with ER-negative cancers, chemotherapy is often a key part of early-stage treatment ^[2].

• Neoadjuvant chemotherapy: This is chemotherapy given before surgery. ER-low tumors frequently have a high rate of pathologic complete response (meaning no cancer is found in the tissue removed during surgery) ^[2]. Achieving a pathologic complete response lowers long-term risk, but it does not guarantee a cure.
• Genomic Testing: Genomic tests (like Oncotype DX) look at the activity of genes within the tumor. While these tests help guide chemotherapy decisions for tumors with higher ER expression, they have limited validation and uncertain predictive value specifically for the ER-low group ^[17][18].
• Making the decision: Your doctor will not rely on a genomic test alone or your ER-low status alone. Chemotherapy recommendations will heavily depend on your tumor’s grade, size, lymph node status, HER2 status, and PR status ^[19][20].